ArriVent BioPharma (AVBP) Total Liabilities (2023 - 2026)

ArriVent BioPharma has disclosed Total Liabilities across 4 years of filings, most recently posting $25.3 million for Q1 2026.

• Total Liabilities for Q1 2026 came in at $25.3 million, up 95.44% year-over-year; the trailing twelve-month figure through Mar 2026 was $25.3 million (up 95.44% YoY), and the FY2025 annual result was $25.9 million, up 50.08% from the prior year.
• Total Liabilities came in at $25.3 million for Q1 2026 at ArriVent BioPharma, down from $25.9 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $132.6 million in Q3 2023 to a low of $10.1 million in Q1 2024.
• The 4-year median for Total Liabilities is $19.6 million (2025), against an average of $40.0 million.
• Across the five-year window, Total Liabilities slumped 89.7% in 2024 and soared 95.44% in 2026, its largest moves.
• ArriVent BioPharma's Total Liabilities stood at $11.8 million in 2023, then jumped by 46.5% to $17.3 million in 2024, then jumped by 50.08% to $25.9 million in 2025, then fell by 2.43% to $25.3 million in 2026.
• The last three Total Liabilities figures came in at $25.3 million (Q1 2026), $25.9 million (Q4 2025), and $21.6 million (Q3 2025), per Business Quant data.